- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03005158
High-Sensitivity Cardiac Troponin On Presentation to Rule Out Myocardial Infarction (HiSTORIC)
High-Sensitivity Cardiac Troponin On Presentation to Rule Out Myocardial Infarction (HiSTORIC): A Stepped Wedge Cluster Randomized Trial
Patients with suspected acute coronary syndrome account for a tenth of all presentations to the Emergency Department and up to 40 per cent of unplanned hospital admissions. The majority of patients do not have a heart attack (myocardial infarction), and may be safely discharged from the Emergency Department.
The investigators propose to evaluate whether the use of the HighSTEACS pathway in patients with suspected acute coronary syndrome reduces length of stay and allows more patients to be safely discharged from the Emergency Department. This pathways utilizes high-sensitivity cardiac troponin I testing and will rule out myocardial infarction if troponin concentrations are <5 ng/L on presentation, with further testing indicated at 3 hours only in those presenting early or with troponin concentrations between 5 ng/L and the 99th centile.
In six secondary and tertiary centres across Scotland, the investigators will introduce the pathway as part of a stepped wedge cluster randomized controlled trial. Sequential hypothesis testing will evaluate the efficacy and safety of the pathway. The primary efficacy end-point will be length of stay from time of presentation until final hospital discharge and the primary safety end-point will be survival free from type 1 or 4b myocardial infarction or cardiac death from discharge to 30 days. The study population will consist of those patients with cardiac troponin concentrations within the normal reference range (<99th centile) at presentation.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All consecutive patients with suspected acute coronary syndrome
- High-sensitivity cardiac troponin I measured as part of routine clinical care
Exclusion Criteria:
- Patients who are not resident in Scotland
- Patients with ST-segment elevation myocardial infarction
- Patients presenting to hospital in cardiac arrest
- Patients with presentation high-sensitivity cardiac troponin I concentrations greater than sex-specific 99th centile thresholds
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Validation Phase
All six hospital sites currently use the ARCHITECT STAT high- sensitive troponin I assay in the assessment of patients with suspected acute coronary syndrome and use sex-specific thresholds upper reference limits (99th centile) to rule out myocardial infarction.
This validation phase of up to 10 months will provide baseline information for each site on patients with suspected acute coronary syndrome in whom myocardial infarction is ruled out.
|
Standard care across all sites during the validation phase will rule out myocardial infarction in those with presentation troponin below the 99th centile with greater than 6 hours of symptoms at the time of blood sampling.
In those with less than 6 hours of symptoms, a second test will be measured 6- 12 hours after presentation.
|
Other: Randomization Phase
Participating centres will be randomized to implement the HighSTEACS pathway (intervention).
The order of implementation will be randomized, with paired participating centres implementing in steps over a 6 month period.
|
Standard care or HighSTEACS pathway.
|
Active Comparator: Implementation Phase
A final phase of up to 10 months after implementation of the HighSTEACS pathway will be matched by calendar month in each site to that of the validation phase, allowing each participating centre to act as its own control and to adjust for seasonal differences in the incidence of myocardial infarction and mortality.
|
Implementation of the HighSTEACS pathway to rule out myocardial infarction in patients with suspected acute coronary syndrome.
Myocardial infarction will be ruled out if presentation cardiac troponin concentrations are <5 ng/L in those with at least 2 hours of symptoms at the time of blood sampling.
In patients with less than two hours of symptoms, or where cardiac troponin concentrations are between 5ng/L and the 99th centile, repeat testing will be recommended at 3 hours.
Myocardial infarction will be ruled out at 3 hours if cardiac troponin concentrations are unchanged (<3 ng/L change) and remain ≤99th centile on retesting.
Those remaining ≤99th centile on retesting but demonstrating a significant change will require admission for further testing at 6-12 hours.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Length of hospital stay (minutes)
Time Frame: Length of time from initial presentation to the Emergency Department until final discharge from hospital, an average of 24 hours.
|
This time frame is unique to each patient
|
Length of time from initial presentation to the Emergency Department until final discharge from hospital, an average of 24 hours.
|
Type 1 or type 4b myocardial infarction or cardiac death after discharge and within 30 days of index admission
Time Frame: Hospital discharge to 30 days after initial presentation
|
Hospital discharge to 30 days after initial presentation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients discharged directly home from the Emergency Department
Time Frame: Presentation to discharge from hospital, an average of 24 hours.
|
Time frame of initial hospital episode is unique to each patient
|
Presentation to discharge from hospital, an average of 24 hours.
|
Type 1 or 4b Myocardial Infarction after hospital discharge (independently double adjudicated using all available clinical information)
Time Frame: Hospital discharge to 30 days and 1 year after initial presentation
|
An adjudicated diagnosis of type 1 and type 4b myocardial infarction will be made in line with the universal definition of myocardial infarction, using all available clinical information.
|
Hospital discharge to 30 days and 1 year after initial presentation
|
Cardiac death after hospital discharge (independently double adjudicated using all available clinical information)
Time Frame: Hospital discharge to 30 days and 1 year after initial presentation
|
Hospital discharge to 30 days and 1 year after initial presentation
|
|
Cardiovascular death after hospital discharge (independently double adjudicated using all available clinical information)
Time Frame: Hospital discharge to 30 days and 1 year after initial presentation
|
Hospital discharge to 30 days and 1 year after initial presentation
|
|
All-cause death after hospital discharge
Time Frame: Hospital discharge to 30 days and 1 year after initial presentation
|
Hospital discharge to 30 days and 1 year after initial presentation
|
|
Unplanned coronary revascularisation after hospital discharge (from cardiac intervention databases and case note review)
Time Frame: Hospital discharge to 30 days and 1 year after initial presentation
|
We will identify any patients who require unplanned percutaneous coronary intervention or coronary artery bypass grafting.
|
Hospital discharge to 30 days and 1 year after initial presentation
|
Proportion of patients re-attending the Emergency Department
Time Frame: Hospital discharge to 30 days and 1 year after initial presentation
|
Hospital discharge to 30 days and 1 year after initial presentation
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pre-specified sub-group analyses of the primary outcome
Time Frame: length of hospital stay defined as the length of time from initial presentation to the Emergency Department until final discharge from hospital; safety follow-up time frame of 30 days and 1 year after hospital discharge
|
We will evaluate if the effect of intervention is significantly stronger or weaker in pre-specified sub-groups by assessing the co-primary endpoints in those who present with cardiac troponin <5 ng/L (low risk group), and in the whole population across different ages (considering age as a continuous variable), by duration of symptoms (considered as a continuous variable), by gender, by those who have or do not have a pre-existing history of ischaemic heart disease, by those with a presentation electrocardiogram suggesting ischaemia, by the GRACE risk score (considered as a continuous variable), and by day of patient presentation (assessing differences in weekday/weekend or routine/out-of-hours presentation).
|
length of hospital stay defined as the length of time from initial presentation to the Emergency Department until final discharge from hospital; safety follow-up time frame of 30 days and 1 year after hospital discharge
|
Cost-effectiveness analysis
Time Frame: 1 year
|
Based on costs of investigation and management in the year after initial hospital presentation
|
1 year
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Shah AS, Anand A, Sandoval Y, Lee KK, Smith SW, Adamson PD, Chapman AR, Langdon T, Sandeman D, Vaswani A, Strachan FE, Ferry A, Stirzaker AG, Reid A, Gray AJ, Collinson PO, McAllister DA, Apple FS, Newby DE, Mills NL; High-STEACS investigators. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. Lancet. 2015 Dec 19;386(10012):2481-8. doi: 10.1016/S0140-6736(15)00391-8. Epub 2015 Oct 8.
- Shah ASV, Anand A, Chapman AR, Newby DE, Mills NL; High-STEACS Investigators. Measurement of cardiac troponin for exclusion of myocardial infarction - Authors' reply. Lancet. 2016 Jun 4;387(10035):2289-2291. doi: 10.1016/S0140-6736(16)30517-7. No abstract available.
- Anand A, Lee KK, Chapman AR, Ferry AV, Adamson PD, Strachan FE, Berry C, Findlay I, Cruikshank A, Reid A, Collinson PO, Apple FS, McAllister DA, Maguire D, Fox KAA, Newby DE, Tuck C, Harkess R, Keerie C, Weir CJ, Parker RA, Gray A, Shah ASV, Mills NL; HiSTORIC Investigatorsdagger. High-Sensitivity Cardiac Troponin on Presentation to Rule Out Myocardial Infarction: A Stepped-Wedge Cluster Randomized Controlled Trial. Circulation. 2021 Jun 8;143(23):2214-2224. doi: 10.1161/CIRCULATIONAHA.120.052380. Epub 2021 Mar 23.
- Ferry AV, Strachan FE, Stewart SD, Marshall L, Lee KK, Anand A, Shah ASV, Chapman AR, Mills NL, Cunningham-Burley S. Exploring Patient Experience of Chest Pain Before and After Implementation of an Early Rule-Out Pathway for Myocardial Infarction: A Qualitative Study. Ann Emerg Med. 2020 Apr;75(4):502-513. doi: 10.1016/j.annemergmed.2019.11.012. Epub 2020 Jan 23.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PG/15/51/31596
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Infarction
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
University Medical Centre LjubljanaCompletedCardiac Arrest | Postresuscitation Syndrome | Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)Slovenia
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SANot yet recruiting
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergCompletedMyocardial Infarction | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial InfarctionGermany
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationActive, not recruitingST Elevation Myocardial Infarction | Non ST Elevation Myocardial InfarctionCanada
-
Bispebjerg HospitalOdense University Hospital; Zealand University Hospital; Hvidovre University... and other collaboratorsRecruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Denmark
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
-
University of LeedsUniversity College, LondonCompletedST-elevation Myocardial Infarction | Non ST-elevation Myocardial Infarction
-
Karolinska InstitutetUppsala University; The Swedish Research CouncilActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionSweden
-
Oslo University HospitalVestre Viken Hospital Trust; University of Oslo; University Hospital of North... and other collaboratorsActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionNorway
Clinical Trials on Validation Phase
-
Centre Hospitalier National d'Ophtalmologie des...Not yet recruiting
-
Outcome ReaAssistance Publique - Hôpitaux de Paris; University Hospital, Clermont-Ferrand and other collaboratorsRecruitingCatheter InfectionFrance
-
Hospices Civils de LyonRecruiting
-
Zurich University of Applied SciencesUniversitat Politècnica de ValènciaCompletedPrevention Harmful Effects
-
Linkoeping UniversityRecruiting
-
Andrzej Frycz Modrzewski Krakow UniversityKarolinska Institutet; University of RzeszowCompleted
-
Ludwig Boltzmann Institute for Digital Health and...Salzburger LandesklinikenCompleted
-
University Hospital, GhentUniversity Ghent; BytefliesRecruitingProgressive Multiple SclerosisBelgium
-
Nicole LindenblattNot yet recruitingTrauma | Limb Injury | Patient Reported Outcome MeasuresSwitzerland